Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice. - UroToday

-

Radium-223 has improved overall survival (OS) and reduced symptomatic skeletal events (SSE) in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases (ALSYMPCA trial). Our aim was to assess clinical and biochemical factors related to survival, safety and survival outcomes of Radium-223 in a clinical practice setting. We retrospectively analysed 32 mCRPC patients treated with Radium-223, assessing bone scan, pain reduction, alkaline phosphatase (ALP) and prostate-specific antigen (PSA) response (≥30% reduction). At scintigraphic assessment, 41% had partial response with a disease control rate of 91%; 56% had ALP response and 25% had PSA response; 41% had pain reduction with pain control of 72%. Scintigraphic response and stability were correlated with longer median progression-free survival (mPFS) (13 and 12 vs. 6 months; P=0.002) and mOS (16 and 12 vs. 6 months; P=0.003). ALP response was associated with longer mPFS (13 vs. 12 months; P=0.2) and mOS (16 vs. 12 months; P=0.2). PSA response was associated with longer mPFS (13 vs. 12 months; P=0.02), whereas mOS could not be computed. Pain response and stability were associated with survival benefit according to mPFS (13 and 12 vs. 9 months) and mOS (both 16 vs. 12 months) without statistical significance. Baseline ALP <220 UI/l, Eastern Cooperative Oncology Group (ECOG) performance status 0 and absence of previous chemotherapy correlated with statistically significantly longer survival outcomes. Skeletal-related events (SRE) occurred in three patients and median time to first SRE was 9.5 months, mPFS was 12 months and mOS 14 months. G3-G4 toxicities developed in 16% of patients. Our results are in line with those reported in the pivotal trial and in other retrospective studies. In conclusion, Radium-223 was associated with high scintigraphic, biochemical and pain response rates and was tolerated well by most patients. Response to Radium-223 and better baseline factors correlated to longer survival in clinical practice experience as in the clinical trial setting.

Oncology letters. 2018 Nov 30 [Epub]

Arsela Prelaj, Sara Elena Rebuzzi, Federica Buzzacchino, Chiara Pozzi, Carla Ferrara, Viviana Frantellizzi, Giulia Anna Follacchio, Liana Civitelli, Giuseppe De Vincentis, Silverio Tomao, Vincenzo Bianco

Department of Radiological, Oncological and Anatomo-Pathological Sciences, 'Sapienza' University of Rome, Policlinico Umberto I, I-00161 Rome, Italy., Department of Medical Oncology, IRCCS San Martino IST, I-16132 Genoa, Italy., Department of Public Health and Infectious Diseases, 'Sapienza' University of Rome, I-00185 Rome, Italy.

PubMed http://www.ncbi.nlm.nih.gov/pubmed/30675201



https://ift.tt/2V2KOU7

Comments

Post a Comment

Popular posts from this blog

I Wish I Didn't Need an Oncologist at All, But I'm Thankful for the One ...

-
Image
efudex side effects :: Article Creator Inmates Given Ivermectin In Jail Will Each Get $2,000 After Settlement Your browser is not supporteddetroitnews.Com detroitnews.Com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use. Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on detroitnews.Com Efudex Cream Efudex Cream Generic Name & Formulations General Description Fluorouracil 5%. Pharmacological Class Antimetabolite. How Supplied Soln (w. Drop dispenser)—10mL, 25mL; Crm—40g Efudex Cream Indications Indications Multiple actinic or solar keratoses. Superficial basal cell carcinoma when conventional therapy is impractical (5% only); see full labeling. Efudex Cream Dosage and Administration Adult Keratoses: Apply twice daily until eros
Read more

Early symptoms of cancer in males: Common warning signs

-
Image
fluciclovine f 18 :: Article Creator The U.S. Navy Might Be Done With The F/A-18 Super Hornet Fighter Will The U.S. Navy Receive Its Final F/A-18 Super Hornets? - Around the holidays, money can be tight, a fact that the United States Navy has also learned as its negotiations to buy the last batch of Super Hornets are reportedly stalled over the growing price tag. USNI News reported on Tuesday that the contract for the U.S. Navy to purchase the final twenty F/A-18 E/F Super Hornets from aerospace giant Boeing appears to be at a standstill. The Navy continues to work with Boeing on the contract for the 20 congressionally added Super Hornet aircraft. Ongoing contract negotiations cannot be discussed at this time," Capt. Michael Burks, the program manager for the F/A-18 and EA-18G office at Naval Air Systems Command, told USNI News in a statement. Previous estimates put the unit cost of the final batch of aircraft at $55.7 million, and la
Read more

20 Famous Men Who Have Had Prostate Cancer

-
Image
leukemia treatment options :: Article Creator Current And Breakthrough Treatments For Chronic Lymphocytic Leukemia (CLL) Chronic lymphocytic leukemia (CLL) is a slow-growing cancer of the immune system. Because it's slow-growing, many people with CLL won't need to start treatment for many years after their diagnosis. Once the cancer begins to grow, there are many available treatment options that can help people achieve remission. This means people can experience long periods of time when there's no sign of cancer in their bodies. The exact treatment option that you'll receive depends on a variety of factors. This includes: whether your CLL is symptomatic the stage of the CLL, based on results of blood tests and a physical exam your age your overall health While there's no cure for CLL yet, breakthroughs in the field are on the horizon. Doctors typically stage CLL using a system called the Rai system. Low
Read more